Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
ORGANIZATION
Annual Price Revisions Will Demotivate Pharmas, Foreign HQs Harboring Serious Concerns: PhRMA Japan Chief
A proposal to revise drug prices annually, which now looms as a real possibility, will demotivate drug makers to develop innovative drugs for Japan, and significantly erode the market’s attractiveness, Patrik Jonsson, chairman of the Japan-based Executive Committee at PhRMA,…
To read the full story
Related Article
- Ongoing Discussions without Chuikyo Deplorable: JPWA Head
December 12, 2016
- Industry Casts Doubt on “1.25 Times” Threshold for Downward Tweak under Foreign Price Adjustment Rule
December 12, 2016
- Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
December 12, 2016
- Health Minister Calls for Structural Change in Pharma Industry
December 12, 2016
- The Sooner the Better, Suga Says on Drug Pricing Revamp
December 12, 2016
- Industry’s “No” to Disclosure of Manufacturing Costs Draws Fire from Chuikyo Reps
December 12, 2016
- (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
December 12, 2016
- Shiozaki Will Bring Chuikyo’s Views to 4-Way Confab, No Paper Planned: Official
December 12, 2016
- (Update) Pharma Trade Groups Express Strong Opposition to Annual Price Revisions: Chuikyo
December 12, 2016
ORGANIZATION
- JPWA Reports No Damage from PHP Vulnerability, Renews “No” to FY2027 Revision
October 23, 2026
- Ex-JMA Vice President, Lawmaker Hanyuda Remembered at Memorial Service
October 21, 2026
- Japan Generics Society Calls for Risk-Based Nitrosamine Controls
October 16, 2026
- Japan Expert Calls for Earlier Access to Anti-Obesity Drugs
October 16, 2026
- Japan Falling Behind US, China in Pharma Innovation, EFPIA Chief Urges Action
October 15, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…